References
- Papi A, Bellettato CM, Braccioni F, et al. Infections and airway inflammation in chronic obstructive pulmonary disease severe exacerbations. Am J Respir Crit Care Med. 2006;173(10):1114–1121.
- Johnston SL, Pattemore PK, Sanderson G, et al. Community study of role of viral infections in exacerbations of asthma in 9-11 year old children. BMJ. 1995;310(6989):1225–1229.
- Fox JP. Is a rhinovirus vaccine possible? Am J Epidemiol. 1976;103(4):345–354.
- Mitchison DA. Prevention of colds by vaccination against a rhinovirus: A report by the Scientific Committee on common cold vaccines. Br Med J. 1965;1(5446):1344–1349.
- Hamory BH, Hamparian VV, Conant RM, et al. Human responses to two decavalent rhinovirus vaccines. J Infect Dis. 1975;132(6):623–629.
- McIntyre CL, Knowles NJ, Simmonds P. Proposals for the classification of human rhinovirus species A, B and C into genotypically assigned types. J Gen Virol. 2013;94(Pt 8):1791–1806.
- Schiller JT, Lowy DR. Raising expectations for subunit vaccine. J Infect Dis. 2015;211(9):1373–1375.
- Maughan CN, Preston SG, Williams GR. Particulate inorganic adjuvants: recent developments and future outlook. J Pharm Pharmacol. 2015;67(3):426–449.
- Gern JE, Dick EC, Kelly EA, et al. Rhinovirus-specific T cells recognize both shared and serotype-restricted viral epitopes. J Infect Dis. 1997;175(5):1108–1114.
- Parry DE, Busse WW, Sukow KA, et al. Rhinovirus-induced PBMC responses and outcome of experimental infection in allergic subjects. J Allergy Clin Immunol. 2000;105(4):692–698.
- Message SD, Laza-Stanca V, Mallia P, et al. Rhinovirus-induced lower respiratory illness is increased in asthma and related to virus load and Th1/2 cytokine and IL-10 production. Proc Natl Acad Sci U S A. 2008;105(36):13562–13567.
- Jackson DJ, Makrinioti H, Rana BM, et al. IL-33-dependent type 2 inflammation during rhinovirus-induced asthma exacerbations in vivo. Am J Respir Crit Care Med. 2014;190(12):1373–1382.
- Ott G, Barchfeld GL, Chernoff D, et al. MF59. Design and evaluation of a safe and potent adjuvant for human vaccines. Pharm Biotechnol. 1995;6:277–296.
- Arakawa T. Adjuvants: no longer a ‘dirty little secret’, but essential key players in vaccines of the future. Expert Rev Vaccines. 2011;10(1):1–5.
- Li X, Aldayel AM, Cui Z. Aluminum hydroxide nanoparticles show a stronger vaccine adjuvant activity than traditional aluminum hydroxide microparticles. J Control Release. 2014;173:148–157.
- Williams GR, Fierens K, Preston SG, et al. Immunity induced by a broad class of inorganic crystalline materials is directly controlled by their chemistry. J Exp Med. 2014;211(6):1019–1025.
- Yan S, Rolfe BE, Zhang B, et al. Polarized immune responses modulated by layered double hydroxides nanoparticle conjugated with CpG. Biomaterials. 2014;35(35):9508–9516.
- Glanville N, McLean GR, Guy B, et al. Cross-serotype immunity induced by immunization with a conserved rhinovirus capsid protein. PLoS Pathog. 2013;9(9):e1003669.
- Edlmayr J, Niespodziana K, Popow-Kraupp T, et al. Antibodies induced with recombinant VP1 from human rhinovirus exhibit cross-neutralisation. Eur Respir J. 2011;37(1):44–52.
- McLean GR, Walton RP, Shetty S, et al. Rhinovirus infections and immunisation induce cross-serotype reactive antibodies to VP1. Antiviral Res. 2012;95(3):193–201.